| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |